Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
JSPR Jasper Therapeutics
1.930+0.150+8.43%
Close
02/03 16:00 ET
1.930-0.000-0.02%
Post Mkt Price 02/03 19:59 ET
High
2.020
Open
1.780
Turnover
4.88M
Low
1.730
Pre Close
1.780
Volume
2.55M
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Jasper Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) ("Jasper"), a biotechnology company focused on developing novel antibody therapies targeting c-Kit (C
William Blair Weighs in on Jasper Therapeutics, Inc.'s Q4 2022 Earnings (NASDAQ:JSPR)
Jasper Therapeutics, Inc. (NASDAQ:JSPR – Get Rating) – William Blair decreased their Q4 2022 EPS estimates for shares of Jasper Therapeutics in a report issued on Monday, January 30th. William Bla
$20 Million Bet On Precigen? Check Out These 4 Penny Stocks Insiders Are Buying
The Dow Jones jumped more than 350 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested i
Fly Intel: After-Hours Movers
Jasper Therapeutics Discloses Carlyle Group Buys $4.7M in Common Stock
Jasper Therapeutics to Host Investor Conference Call and Webcast on January 31, 2023
REDWOOD CITY, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) ("Jasper"), a biotechnology company focused on developing novel antibody therapies targeting c-Kit (C
Jasper Therapeutics Raises $103.5 Million From Public Offering of Shares
01:52 PM EST, 01/27/2023 (MT Newswires) -- Jasper Therapeutics (JSPR) said Friday it raised gross proceeds of $103.5 million from an underwritten public offering of 69 million shares at a price of $1.
Press Release: Jasper Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Jasper Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares REDWOOD CITY, Calif., Jan. 27, 2023 (GLOBE NEWSWIRE) -
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Major Shareholder Holding Ltd Roche Sells 75,000 Shares
Jasper Therapeutics, Inc. (NASDAQ:JSPR – Get Rating) major shareholder Holding Ltd Roche sold 75,000 shares of Jasper Therapeutics stock in a transaction dated Wednesday, January 25th. The shares wer
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersAkanda (NASDAQ:AKAN) stock increased by 28.2% to $0.36 during Thursday's after-market session. Akanda's trading volume hit 4.1 million shares by close, accounting for 474.8% of its average volu
Company Overview
More
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. It focuses on the development and commercialization of safer, stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company was founded by Judith Shizuru and Susan Prohaska in March 2018 and is headquartered in Redwood City, CA.
CEO： Mr. Ronald A. Martell
Market： NASDAQ
Listing Date： 01/10/2020
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet